Breaking News: Human BioSystems Corroborates Organ Preservation Survival Study Results With Functional Biochemical Marker Testing.

PALO ALTA, Calif. -- Human BioSystems (OTCBB:HBSC), developer of preservation platforms for organs and other biomaterials, announces today that the organ preservation survival studies announced in press releases dated October 19th, 2005 and December 19th, 2005 are now further supported by biochemical and histological test results.

The survival studies announced in earlier press releases had shown that kidneys stored using the company's patent pending "HBS-AZ" preservation process and solution exhibited an animal survival rate of 80%, compared to a 10% survival rate of animals using the currently used European standard "HTK" solution.

"The survival studies are now further corroborated by biochemical testing of the preserved renal function through the measurement of serum creatinine and blood urea nitrogen (BUN)," according to Dr. Luis Toledo, HBS Chief Medical Officer.

Dr. Toledo continued that "The animals with kidneys stored using the company's proprietary HBS-AZ preservation solution had normal serum creatinine levels after 4 and 7 days of survival, whereas the animals stored in the HTK solution had abnormally elevated creatinine levels explaining why 90% of the HTK animals died within 4 days after transplantation as seen in the earlier survival studies."

"Similar results were obtained using the BUN testing. This showed that the HBS-AZ stored kidneys were functioning normally, while the HTK stored kidneys revealed marked functional abnormalities indicating that they were unable to remove the urea waste products from the blood."

Dr. Toledo also stated that "The survival studies were further supported by histological tests involving the examination of cross sections of the kidney under a microscope using a scientifically accepted gradation of histological damage to the cells. HBS-AZ stored kidneys revealed only small areas of damage and cell death with predominantly normal architecture and appearance. In contrast, the HTK stored kidneys had large areas of injury, compromised cell integrity and cell death."

Dr. David Winter, HBS President, concluded by stating "If we can achieve similar results with human kidneys, the ability to store and preserve kidneys for longer periods of time before transplantation provides a better donor to recipient matching of the organ. A better match would most probably increase the success rate of organ transplants and reduce complications following transplantation. This could save medical costs and may increase the quality of life of the recipient through reduction of the need for immunosuppressant drugs."

HBS is headquartered in Palo Alto, California with research facilities in Michigan.

Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.

Human BioSystems (OTC Bulletin Board:HBSC)